CVS Health (Caremark) (CVS)
The desk's stance
On our research list, not on the slate.
What the company does
Pharmacy powerhouse plus Caremark: after making Wegovy preferred in 2025, the PBM announced it will add Zepbound back as a preferred option effective October 1, 2026, and unblocked oral Foundayo in June 2026, demonstrating its pricing leverage over both duopolists.
In short: Healthcare benefits and pharmacy services. Category: Integrated Managed Care Pharmacy. Sector: Healthcare, Healthcare Plans.
G-Street Value and Score
G-Street Value: $110.34, computed Oct 18, 2026 (confidence: medium).
How we got there: 70% analyst leg $110.34 (5 analyst targets, credibility- and freshness-weighted, after 8% optimism discount) + 30% GainStreet factor value $133.26 (15.61× fwd EPS anchored to healthcare multiples) — capped at the analyst leg; factors never out-bull the street.
G-Street Score: 41 out of 100 (Weak).
- Top-line growth & guidance: 7 of 32
- Margin power: 3 of 15
- Revenue visibility & quality: 6 of 11
- Profitability & balance sheet: 15 of 24
- Capital allocation & governance: 3 of 6
- Valuation, sentiment & momentum: 7 of 12
Our current thesis
Updated Oct 17, 2026
The thesis
- Consecutive EPS beats and guidance hikes demonstrate medical benefit ratio normalization across Aetna books.
- Discounted 10.8x forward P/E trades at a steep multiple discount to peer UNH.
- Trailing free cash flow of $11.8B supports ongoing balance sheet deleveraging and secure dividends.
Risks
- Caremark faces elevated FTC scrutiny and legislative reform over pharmacy benefit manager rebate models.
- High total debt of $76.3B constrains capital deployment and share repurchases.
- Medicare Advantage Star rating shifts threaten reimbursement rates and future quality bonus payments.
What we're watching
- Q3 2026 earnings release on November 4, 2026, evaluating medical cost trends.
- CMS 2027 Medicare Advantage Star ratings impact on multi-year pricing and rebates.
- Cash flow generation tracking toward the raised full-year target of $11.5B.
Latest
CVS trades around $92.36 at 10.8x forward earnings following a sharp post-summer rebound, backed by four consecutive quarterly EPS beats including Q2 2026 adjusted EPS of $2.58 versus $1.85 expected on 7.1% YoY revenue growth. Management raised full-year 2026 adjusted EPS guidance to $7.90–$8.10 and operating cash flow targets to at least $11.5B as Aetna medical loss ratios stabilized. Trailing twelve-month free cash flow reached $11.8B, providing crucial deleveraging capacity against $76.3B in debt ahead of Q3 earnings on November 4, 2026.
Key numbers
As of Oct 16, 2026: market cap $118.1B · revenue growth +7.1% year over year · gross margin 13.6% · net margin 1.2% · forward P/E 10.8 · next earnings Nov 4, 2026.
Analyst price targets
Published analyst targets we could trace to a named source.
- UBS, Buy: $118 target (September 2026). Source: benzinga.com
- Evercore ISI, Outperform: $125 target (August 2026). Source: benzinga.com
- JPMorgan, Overweight: $118 target (August 2026). Source: benzinga.com
- Wells Fargo, Overweight: $123 target (July 2026). Source: benzinga.com
- Bank of America, Buy: $110 target (June 2026). Source: benzinga.com
On the Gainz Lab maps
Who it does business with
- Novo Nordisk supplies CVS Health (Caremark) — Formulary preferred. Caremark kept Wegovy as a preferred GLP-1 on commercial formularies while negotiating rebate terms with both duopolists.
- Eli Lilly supplies CVS Health (Caremark) — Formulary restoration. CVS Caremark restored Zepbound to preferred status for October 2026 and removed the new-to-market block on Foundayo.
- UnitedHealth competes with CVS Health (Caremark) — Managed-care rivals. Optum vs Caremark: two vertically integrated healthcare giants fighting over employer contracts, PBM rebates, and specialty pharmacy margins.